Equity Overview
Price & Market Data
Price: $8.77
Daily Change: +$0.26 / 2.96%
Daily Range: $8.57 - $8.80
Market Cap: $241,880,320
Daily Volume: 4,143
Performance Metrics
1 Week: 23.33%
1 Month: 19.69%
3 Months: 33.59%
6 Months: -62.28%
1 Year: -6.33%
YTD: 38.83%
Company Details
Employees: 111
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.